

Resource Summary Report

Generated by [nidm-terms](#) on Aug 6, 2026

Alzheimers Drug Discovery Foundation

RRID:SCR_007397

Type: Tool

Proper Citation

Alzheimers Drug Discovery Foundation (RRID:SCR_007397)

Resource Information

URL: <http://www.alzdiscovery.org>

Proper Citation: Alzheimers Drug Discovery Foundation (RRID:SCR_007397)

Description: The Alzheimers Drug Discovery Foundation (ADDF) is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimers disease, related dementias and cognitive aging. Founded in 1998 by the Este Lauder family, the ADDF awards grants to leading scientists conducting breakthrough drug discovery research. We use a venture philanthropy model to bridge the worldwide funding gap between basic research and later-stage drug development, using any return on investment to support new research. We have granted more than 40 million to fund over 295 Alzheimers drug discovery programs in academic centers and biotechnology companies in 15 countries. Scientists funded by the ADDF have entered clinical trials with several new drugs. The ADDF has invested over 8 million in 40 biotechnology companies, which have received follow-on commitments of over 1 billion. **Keywords:** Research, Funding, Alzheimer's, Drug, Discovery, Biotechnology, Biomedical, Development, Investment, Prevention, Treatment, Cure, Cognitive, Aging, Dementia, Disease,

Synonyms: ADDF

Resource Type: data or information resource, training material, portal, narrative resource, bibliography, funding resource, disease-related portal, topical portal

Related Condition: Aging

Resource Name: Alzheimers Drug Discovery Foundation

Resource ID: SCR_007397

Alternate IDs: nif-0000-00450

Record Creation Time: 20220129T080241+0000

Ratings and Alerts

No rating or validation information has been found for Alzheimers Drug Discovery Foundation.

No alerts have been found for Alzheimers Drug Discovery Foundation.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Wu CY, et al. (2025) Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: a population-based cohort study. *Alzheimer's research & therapy*, 17(1), 269.

Jaam M, et al. (2021) Using Assessment Design Decision Framework in understanding the impact of rapid transition to remote education on student assessment in health-related colleges: A qualitative study. *PloS one*, 16(7), e0254444.

Kang PL, et al. (2021) Reaction prediction via atomistic simulation: from quantum mechanics to machine learning. *iScience*, 24(1), 102013.

Wang J, et al. (2020) Small-Baseline Approach for Monitoring the Freezing and Thawing Deformation of Permafrost on the Beiluhe Basin, Tibetan Plateau Using TerraSAR-X and Sentinel-1 Data. *Sensors (Basel, Switzerland)*, 20(16).

Maes T, et al. (2020) Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations. *PloS one*, 15(5), e0233468.

Dean HB, et al. (2019) Neurodegenerative Disease-Associated Variants in TREM2 Destabilize the Apical Ligand-Binding Region of the Immunoglobulin Domain. *Frontiers in neurology*, 10, 1252.

Zhang Z, et al. (2019) Permafrost Deformation Monitoring Along the Qinghai-Tibet Plateau Engineering Corridor Using InSAR Observations with Multi-Sensor SAR Datasets from 1997-2018. *Sensors (Basel, Switzerland)*, 19(23).

F?? M, et al. (2016) Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory. *Scientific reports*, 6, 19393.

Pitman MC, et al. (2015) Intravenous therapy duration and outcomes in melioidosis: a new treatment paradigm. *PLoS neglected tropical diseases*, 9(3), e0003586.

Izzo NJ, et al. (2014) Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PloS one, 9(11), e111899.

Trushina E, et al. (2012) Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. PloS one, 7(2), e32737.

Sanz-Arigita EJ, et al. (2010) Loss of 'small-world' networks in Alzheimer's disease: graph analysis of fMRI resting-state functional connectivity. PloS one, 5(11), e13788.

Cashman JR, et al. (2008) Immune defects in Alzheimer's disease: new medications development. BMC neuroscience, 9 Suppl 2(Suppl 2), S13.